The Yellow fever vaccine vYF represents a potential breakthrough in preventing infectious diseases for international travelers. Historically, manufacturing these vaccines in eggs limited the global supply during major outbreaks. In contrast, this next-generation candidate utilizes serum-free Vero cells for more efficient production. Consequently, researchers conducted a phase 2 trial to compare its performance against the standard YF-VAX. The study enrolled healthy adults between 18 and 60 years of age to ensure broad relevance.
Trial Results for the Yellow fever vaccine vYF
Specifically, the primary goal was to demonstrate that vYF is not inferior to the licensed vaccine. Researchers found that 99.7% of participants receiving vYF achieved seroconversion by day 29. Similarly, 99.4% of those receiving the standard YF-VAX showed a comparable immune response. Because the lower limit of the confidence interval remained above the -5% threshold, the trial met its primary endpoint. Additionally, antibody levels remained comparable and robust throughout the first year of follow-up.
Safety Profiles and Global Impact
Furthermore, the safety outcomes between the two vaccine groups appeared remarkably similar. Most participants reported common side effects like local pain or fatigue after the injection. However, no serious safety concerns or unexpected adverse events occurred during the observation period. Therefore, this vaccine could provide a more stable and scalable option for global health programs. In conclusion, the vYF candidate offers a reliable alternative that matches the current gold standard.
Frequently Asked Questions
Q1: How does vYF differ from the traditional yellow fever vaccine?
Traditional vaccines use chicken eggs for production, whereas the vYF candidate uses Vero cell technology. This shift allows for faster and more scalable manufacturing.
Q2: Is the vYF vaccine safe for adults?
The phase 2 trial showed that vYF has a safety profile similar to the licensed YF-VAX. Specifically, no major safety concerns appeared during the study.
References
- Feroldi E et al. Immunogenicity and Safety of vYF, a Yellow Fever Vaccine – A Phase 2 Trial. N Engl J Med. 2026 Apr 09. doi: 10.1056/NEJMoa2505665. PMID: 41950474.
- MedPage Today. Next-Gen Yellow Fever Vaccine Hits the Mark in Mid-Stage Trial. Published April 08, 2026.
- ClinicalTrials.gov. Investigational Yellow Fever Vaccine vs Standard Vaccine for Yellow Fever (VYF02 Trial). NCT04942210.